Session Time: 1:15pm-2:45pm
Location: Agora 3 West, Level 3
Objective: To evaluate the profile of fatigue in PD patients between two groups
Background: Parkinson’s disease (PD) is neurodegenerative, presenting motor and non-motor symptoms. Fatigue is the most debilitating symptom among patients with PD (Nassif, 2018) with a prevalence of 28% to 58% (Serrano-Dueñas et al., 2018).
Method: METHODS: A prospective study performed at the Center of Neurosciences of the Hospital das Clínicas of the Federal University of Goiás, Goiânia, Goiás, Brazil. For both groups, participants of both sexes, aged between 20 and 70 years, were included. Neuropsychiatric assessment included the MMSE to measure global cognitive status, and the HAMD and BDI to rate depressive symptoms. Clinical assessment of patients with PD included the Unified Parkinson’s Disease Rating Scale (UPDRS) and Hoehn and Yahr (H-Y) stage. Schwab and England (SE), for evaluation of motor severity and disease stage of each patient were used. The presence and severity of fatigue were assessed with the Chalder Scale and Fatigue Severity Scale (FSS) respectively.
Results: The study included 77 subjects (37 GDP and 40 GC). Regarding FSS, the data did not show significant difference between the groups. With regard to depression, it was more frequent in the GDP at moderate and severe levels (ρ = 0.007) for EH and mild and severe (ρ = 0.016). For the fatigue – age relationship, it is more present among individuals between 50 and 70 years. In the GDP ratio between fatigue and time in disease, the data showed that 46.7% had a duration equal to or greater than 5 years, and by FSS 50%, at the same disease time, they had extreme fatigue. In AVDs, according to SE, only 5% of participants had 60% performance, 5% had 70%, 65% had 80% and 26% had 90% in AVDs.
Conclusion: This study demonstrated that fatigue significantly affects PD patients. It also showed that it is more frequent in those patients with greater time and severity of the disease. Faced with this debilitating condition, it is important to implement combined therapeutic approaches in early diagnosis to provide better quality of life for patients.
References: Nassif & Pereira. Fatigue in Parkinson’s disease: concepts and clinical approach. Psychogeriatric. vol 12(2), 2018. https://doi.org/10.1111/psyg.12302 Serrano-Dueñas et al. Fatigue in Parkinson’s disease: Metric properties of the fatigue impact scale for daily use (D-FIS), and its impact on quality of life. Clinical Neurology and Neurosurgery. Volume 169, June 2018, Pages 12-15. https://doi.org/10.1016/j.clineuro.2018.03.020
To cite this abstract in AMA style:D. Silva, TR. Alcântara-Silva, AL. Alcântara-Silva, S. Suzuki-Godoy. Fatigue in Parkinson’s Disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/fatigue-in-parkinsons-disease/. Accessed December 7, 2023.
« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/fatigue-in-parkinsons-disease/